Epigenetic therapy (decitabine) shows promise for endocrine-resistant breast cancer

[Split]

Using a low dose of the epigenetic therapy drug decitabine, which is currently used to treat some blood cancers, the researchers significantly suppressed the growth of endocrine resistant breast tumours in mice and increased survival time by 90%. The finding, which will be tested in a future Phase I clinical trial, is a potential gamechanger for the more than 4,000 people who are diagnosed with endocrine-resistant breast cancer each year in Australia alone.

This research has uncovered a completely new approach to treating endocrine-resistant breast cancer. In our study, we have not only pinpointed a new molecular mechanism that explains how endocrine resistance might develop – we have identified a treatment currently used in the clinic that can target this mechanism precisely,” says Professor Susan Clark, Head of the Cancer Epigenetics Laboratory at Garvan and senior author of the paper published in Nature Structural & Molecular Biology.

nature.com/articles/s41594-...

[Hazelgreen]

Thanks for posting, Split. This approach sounds very promising!

[LibraryGeek]

That sounds very hopeful- I am experiencing resistance so any new options welcome x

[Praising]

are you in the study? I hope so. Thanks

[Split in reply to Praising]

My understanding is they will start clinical trials next year. Will ask in Garvan and see what they say. But given that it is already tested and approved for some blood cancers hopefully this proposed trial would be moving faster from concept to realisation.